
Please try another search
Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological and infectious diseases. It offers Temodex/SI-053, a therapy to treat malignant brain tumors; and SA033, a therapy to treat cancers in liver. The company is also developing Belopenem for the treatment of bacterial pneumonia. Double Bond Pharmaceutical International AB (publ) was incorporated in 2014 and is based in Uppsala, Sweden.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review